Evidence map›Paper›PMID 29567820›Full record

ArticleThe oncologist2018

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ryo Ko, Takehito Shukuya, Yusuke Okuma, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, Keisuke Azuma and 12 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Review
  10. Article
  11. Multi-institutional survey of thymic carcinoma patients in Hokushin region.Journal of cancer research and clinical oncology · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 1 country.

Ryo KoDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takehito ShukuyaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan tshukuya@juntendo.ac.jp.
Yusuke OkumaDepartment of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital, Tokyo, Japan.
Kazunari TateishiFirst Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Hisao ImaiDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Japan.
Shunichiro IwasawaDepartment of Respirology, Chiba University Graduate School of Medicine, Chiba, Japan.
Eisaku MiyauchiDepartment of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan.
Akiko FujiwaraDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.
Tomohide SugiyamaDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
Keisuke AzumaDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Keiko MurakiDepartment of Respiratory Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan.
Masahiro YamasakiDepartment of Respiratory Disease, Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Hisashi TanakaDepartment of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Yuta TakashimaFirst Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Sayo SodaDepartment of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi, Japan.
Osamu IshimotoDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Nobuyuki KoyamaDepartment of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kunihiko KobayashiDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.
Toshihiro NukiwaJapan Anti-Tuberculosis Association, Tokyo, Japan.
Kazuhisa TakahashiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
North East Japan Study Group
Juntendo University · JPSaitama Medical University · JPChiba University · JPDokkyo Medical University · JPFukushima Medical University · JPHirosaki University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHokkaido University · JPJapan Anti Tuberculosis Association · JPJuntendo University Urayasu Hospital · JPKyoto University · JPSendai Kousei Hospital · JPShinshu University · JPTochigi Cancer Center · JPTohoku University Hospital · JPTokyo Medical University Hachioji Medical Center · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic factors and the efficacy of first-line chemotherapy remain unclear in patients with advanced thymic carcinoma. MATERIALS AND

methodsWe conducted a multi-institutional retrospective study named NEJ023 for patients with advanced thymic carcinoma. All patients without any indication of curative treatment were treated with chemotherapy from 1995 to 2014 at 40 institutions of the North East Japan Study Group.

resultsA total of 286 patients with advanced thymic carcinoma were analyzed. First-line chemotherapy included platinum-based doublets in 62.2% of the patients, monotherapy in 3.5%, and other multidrug chemotherapy (e.g., cisplatin, doxorubicin, vincristine, and cyclophosphamide [ADOC]) in 34.3%. The median follow-up period was 55.5 months, and the median overall survival (OS) from the start of first-line chemotherapy was 30.7 months (95% confidence interval, 25.9-35.9 months). There was no significant difference in OS among different first-line chemotherapy regimens (e.g., between carboplatin/paclitaxel and ADOC, median OS: 27.8 vs. 29.9 months). Masaoka-Koga stage IVa and volume reduction surgery were favorable prognostic factors for OS in the multivariate analysis using the Cox proportional hazards model.

conclusionThe efficacy of each first-line chemotherapy regimen for advanced thymic carcinoma did not vary significantly. Our results might support the adequacy of the use of carboplatin/paclitaxel as first-line chemotherapy for these patients. IMPLICATIONS FOR PRACTICE: Because of its rarity, there is limited information about prognostic factors and efficacy of chemotherapy in patients with advanced thymic carcinoma. This is the largest data set for those patients treated with chemotherapy. This study suggests there is no significant difference in efficacy between carboplatin/paclitaxel and cisplatin/doxorubicin/vincristine/cyclophosphamide for advanced thymic carcinoma. This result can support the adequacy of the selection of platinum doublets as treatment for those patients, rather than anthracycline-based multidrug regimen.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesThymomaYoung AdultChemotherapyMasaoka‐Koga stageThymic carcinomaVolume reduction surgery

Identifiers

PMID29567820
PMCPMC6263125
OpenAlexW2789283644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.